Life Sciences & Healthcare

Each year, the incidence of transplants is increasing. Consequently, population of patients with Graft-versus-Host Disease (GvHD) is on the rise. This is especially true for chronic GvHD for which the incidence has been recorded as high as 80%. The frontline treatment is dominated by corticosteroids and other immunosuppressants. However, the refractory nature of the disease requires patients to move on to later lines of treatment, which currently are limited.

Almost 80-85% of the post-menopausal women population in the world suffer from vasomotor symptoms (VMS) such as hot flashes, night sweats and other associated symptoms. However, due to the stigma and misinformation associated with women’s health and especially menopause, it still remains an area that is understudied in research, often misunderstood by healthcare providers and patients, and unaddressed by most healthcare policies.

As a central driving force for precision medicine worldwide, the Personalized Medicine Coalition (PMC) noted that more than 220 FDA-approved therapies with a biomarker mentioned in the label as ‘essential’ or ‘recommended for prescribing’ were available in the US market between 2015 and 2021. Further fuelling the movement of value-based care, a drug-diagnostic co-development model has been significantly prevalent, leading to a consistently growing usage of companion diagnostics assays – to target patients expected to benefit most from targeted therapy. As of 2022, 40+ commercialized CDx assays were listed exhaustively in the FDA’s List of Cleared or Approved Companion Diagnostic Devices.

Acute Myeloid Leukemia (AML) is a uniquely challenging disease in which 50-80% patients eventually relapse following induction and/or post-remission therapies and with 5-year survival rate of merely 30%. Drug development in AML has been challenging in the past, with multiple failures and modest commercial success.

The Evalueserve medtech team summarizes highlights from key medical devices and diagnostic players presented and discussed at JP Morgan Healthcare Conference 2023.

Digital healthcare gained great prominence following the outbreak of COVID-19, as patients wanted to feel more empowered than ever before. Many venture funds stepped up to fund advanced digital health technology companies that were focused on AI-based data-driven connected technologies.

Globally, we expect to see some clear logistics and demand disruption for the pharmaceutical industry overall, but relatively far less than is likely to be seen in most other industries/sectors. North America and EMEA are expected to invest significantly in API facilities to reduce their dependency on APAC.